CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of ...

PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ... have been accepted for presentation at the 2025 American Society of Clinical Oncology (“ASCO”) Annual ...

“This presentation reflects our focus on developing non-invasive, scalable diagnostics rooted in the promise of liquid biopsy innovation,” said Holly Magliochetti, CEO of PanGIA Biotech.

Presenter: Katharine Price, M.D., Associate Professor of Oncology, Head and Neck Disease Group, Mayo Clinic Comprehensive Cancer Center, and Principal Investigator of the VERSATILE-003 clinical ...

CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American ... the efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual ...

today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc., and Genetics Institute of America has been accepted for presentation at the 2025 Annual Meeting of ...